Celltrion to cut Remsima price by 50% for low-income households

Celltrion, a local biopharmaceutical company, said it will cut the insurance price of its antibody biosimilar product “Resima” by 50 percent for low-income patients who are not covered by the national health insurance scheme.

To this end, Celltrion signed an agreement with the Korea Medical Assistance Foundation (KMAF) on Tuesday based on its social contribution program.

Depending on thei...